GlassScriptPhysician profile
Stanley R Dennison
NPI 1376618470
$16,383.41
in general payments reported to CMS, 2019-2025
33 companies · $14K in 2025
The $14K reported for 2025 was more than what 95% of Interventional Pain Medicine providers received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $559 · 2020: $532 · 2021: $620 · 2022: $554 · 2023: $25.00 · 2024: $68.23 · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Debt Forgiveness: $13K · Food and Beverage: $721 · Travel and Lodging: $701.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Debt Forgiveness | $12,696.41 |
| Food and Beverage | $721.17 |
| Travel and Lodging | $700.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Olympus America INC. | $12,696.41 | 2023-2025 | Evis Exera III Video System Center, Gastrointestinal Videoscope, Evis Exera III Xenon Light Source |
| Si-Bone, INC. | $760.60 | 2025 | |
| Scilex Pharmaceuticals INC. | $444.04 | 2020-2022 | |
| Boston Scientific Corporation | $324.15 | 2019-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $316.81 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $209.80 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $192.42 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $168.62 | 2019-2022 | |
| Stryker Corporation | $154.71 | 2025 | Optablate |
| Stimwave Technologies Incorporated | $130.00 | 2019 | |
| Amgen INC. | $123.97 | 2019-2022 | |
| Venclose INC. | $106.67 | 2020 | |
| Abbvie INC. | $86.69 | 2021-2022 | |
| Tersera Therapeutics LLC | $82.16 | 2019-2024 | Prialt |
| Vericel Corporation | $82.06 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $61.33 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Ibsa Pharma INC. | $54.56 | 2020-2021 | |
| Medela LLC | $41.83 | 2020 | |
| Horizon Therapeutics Plc | $40.21 | 2022 | |
| Indivior INC. | $32.50 | 2025 | Sublocade |
| Protega Pharmaceutials INC | $32.44 | 2025 | Roxybond |
| Allergan, INC. | $30.76 | 2020 | |
| Collegium Pharmaceutical, INC. | $27.35 | 2022-2024 | Belbuca |
| Daiichi Sankyo INC. | $21.77 | 2019 | |
| Stratus Medical, LLC | $21.00 | 2021 | |
| Averitas Pharma INC. | $20.18 | 2025 | Qutenza |
| Radius Health, INC. | $19.60 | 2021 | |
| Electronic Waveform Lab, INC. | $19.52 | 2019 | |
| Biodelivery Sciences International, INC. | $18.48 | 2021 | |
| Fidia Pharma USA INC. | $18.29 | 2024 | Hym/Hyn |
| Medtronic, INC. | $18.05 | 2025 | Inceptiv |
| Novo Nordisk INC | $13.63 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Dennison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.